TY  - JOUR
T1  - COmposite end points in clinical trials
AU  - Sheehe PR
Y1  - 2010/05/05
N1  - 10.1001/jama.2010.522
JO  - JAMA
SP  - 1698
EP  - 1698
VL  - 303
IS  - 17
N2  - 
To the Editor: In their Commentary on the use of composite end points in clinical trials, Drs Tomlinson and Detsky1 asked why the clinical trial of rosiglitazone2 used the primary outcome of diabetes or death. Although the authors discussed various (often problematic) reasons for using composite end points, they did not consider an important legitimate reason for combining death with another end event: to focus on the long-term risk of the end point.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.522
UR  - http://dx.doi.org/10.1001/jama.2010.522
ER  -